This article was originally published in The Gray Sheet
Acquisition of nucleic acid testing technology developer Xtrana by in vitro diagnostic reagent maker Biopool International under a definitive stock-swap agreement announced May 4 is valued at about $9.5 mil. based on Biopool's May 4 closing price of $1.01 per share. Under the terms of the deal, all outstanding shares of Xtrana will be converted into approximately 9.4 mil. newly issued Biopool shares. As a result, current Xtrana and Biopool stockholders will hold about 50% of the combined company
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.